Frontier pharma: ovarian cancer identifying and commercializing first in class innovation

Research Focused On the Frontier Pharma Ovarian Cancer ­ Identifying and Commercializing First­in­Class Innovation "The Report Frontier Pharma: Ovarian Cancer ­ Identifying and Commercializing First­ in­Class Innovation provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. ­ MarketResearchReports.biz" Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five­year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later­stage disease is largely reliant on cytotoxic chemotherapy regimens.

A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast to the market. With the diversity in the pipeline, there is hope that innovative products can make it to market to provide patients with greater therapeutic options, while meeting unmet needs within ovarian cancer. There are 179 ovarian cancer pipeline products associated with a first­in­class molecular target representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. Such a diverse and innovative pipeline implies that approaches to ovarian cancer treatment are changing and first­in­class development is playing a significant role in this.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/499491 Scope Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset.     

What survival benefits do current therapies provide?

What are the current unmet needs that the pipeline needs to address?

The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt. What potential do mAbs have in ovarian cancer treatment?

Will pipeline diversity translate to clinically and commercially successful therapies?

          

How are common target families, such as intracellular signal transduction associated with pathophysiology?

52% of pipeline products act on a first­in­class target, which is higher than the oncology and industry averages.

Do first­in­class products show strong progression into the later stages?

Why is the greatest number of first­in­class products seen in signal transduction?

First­in­class products differ substantially in their clinical potential, based on their alignment to disease causing pathways How well are first­in­class targets, such as Notch, aligned to known disease causing pathways?

Which targets are specifically found in early­stage development?

What is the industry­wide interest in these targets?

Co­development deals for first­in­class products are typically higher value than non­first­in­class counterparts.

To what extent does first­in­class status influence deal value and phase?

Can biologics command a greater deal value than other molecule types?

Reasons to buy This report will allow you to  

 



Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.

Visualize the composition of the ovarian cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.

Analyze the ovarian cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating ovarian cancer.

Assess the therapeutic potential of first­in­class targets. Using a proprietary matrix, first­in­class products have been assessed and ranked according to clinical potential. Promising early­stage targets have been further reviewed in greater detail.

Identify commercial opportunities in the ovarian cancer deals landscape by analyzing trends in licensing and co­development deals and producing a curated list of ovarian cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports­ biz Table of Contents 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3

2 Executive Summary 4 2.1 Significant Unmet Needs in the Ovarian Cancer Market 4 2.2 High Proportion of First­in­Class Innovation offers Promise in Ovarian Cancer 4 2.3 Deal Activity Varies with First­in­Class Status 4 3 The Case for Innovation 5 3.1 Growing Opportunities for Biologic Products 6 3.2 Diversification of Molecular Targets 6 3.3 Innovative First­in­Class Product Developments Remain Attractive 6 3.4 Regulatory and Reimbursement Policy Shifts Favor First­in­Class Product Innovation 7 3.5 Sustained Innovation 7 3.6 GBI Research Report Guidance 8 4 Clinical and Commercial Landscape 9 4.1 Disease Overview 9 4.2 Disease Symptoms 9 4.3 Epidemiology and Etiology 9 4.4 Pathophysiology 10 4.4.1 High­Grade Serous Subtype 10 4.4.2 Low­Grade Serous Subtype 11 4.4.3 Mucinous Carcinoma Subtype 11 4.4.4 Endometrioid Carcinoma Subtype 11 4.4.5 Clear Cell Carcinoma Subtype 11 4.5 Diagnosis 12 4.6 Prognosis 12 4.7 Treatment Algorithm 12 4.7.1 Surgery 12 4.7.2 First­Line Therapy 12 4.7.3 Maintenance Therapy 14 4.7.4 Recurrent Disease and Second­Line Therapy 15 About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Mr. Nachiket State Tower 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +1­518­621­2074 Website: http://www.marketresearchreports.biz/ E: sales@marketresearchreports.biz